LSTA · Lisata Therapeutics, Inc. · Documents
$1.00
-0.01 (-0.91%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and existing capital resources, management has concluded that there is substantial doubt regarding our ability to continue as a going concern for a period of twelve months from the date of issuance of the accompanying consolidated financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$8.97M
Shares
9.01M
Volume · Oct 23
45.56K
Avg daily vol (3M)
295.64K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| DEF 14A | Lisata Therapeutics' proxy seeks stockholder approval for the conversion of Series C Preferred Stock issued in its completed Marea acquisition, a 1-for-5 to 1-for-15 reverse stock split, the 2026 Equity Incentive Plan and ESPP, and a planned rename to Marea Therapeutics, Inc. (symbol MREA). | 2026-10-19 | 2026-11-09 | |
| ARS | — | 2026-10-19 | 2025-12-31 | |
| 8-K | Lisata Therapeutics appointed Jeffrey Farrow to a newly created Class III seat, expanding its Board from seven to eight members effective October 13, 2026. Farrow also joined the Audit Committee, and the Board determined he is independent under Nasdaq Capital Market listing requirements. | 2026-10-14 | 2026-10-13 | |
| PRE 14A | Lisata completed its September 17, 2026 acquisition of Marea Therapeutics and an approximately $225 million private placement; stockholders will vote on preferred-stock conversion, a possible [1-for-5 to 1-for-10] reverse split, and other proposals on November 9, 2026. | 2026-10-07 | 2026-11-09 | |
| 8-K | — | 2026-09-17 | — | |
| 10-Q | — | 2026-08-06 | 2026-06-30 | |
| 8-K | — | 2026-08-04 | 2026-08-03 | |
| SC TO-T/A | — | 2026-07-28 | — | |
| 8-K | — | 2026-07-24 | — | |
| SC 14D9/A | — | 2026-07-21 | — | |
| 8-K | — | 2026-07-17 | 2026-07-16 | |
| SC 14D9/A | — | 2026-07-17 | — | |
| SC TO-T/A | — | 2026-07-17 | — | |
| SC 14D9/A | — | 2026-07-13 | — | |
| SC TO-T/A | — | 2026-07-10 | — | |
| SC 14D9/A | — | 2026-07-02 | — | |
| SC TO-T | — | 2026-06-10 | — | |
| SC 14D9 | — | 2026-06-10 | — | |
| 8-K | — | 2026-06-09 | 2026-06-08 | |
| 8-K | — | 2026-06-01 | — | |
| SC TO-C | — | 2026-06-01 | — | |
| 8-K | — | 2026-05-29 | — | |
| SC TO-C | — | 2026-05-29 | — | |
| 10-Q | — | 2026-05-11 | 2026-03-31 | |
| SC TO-C | — | 2026-05-04 | — | |
| 8-K | — | 2026-05-04 | 2026-05-03 | |
| 10-K/A | — | 2026-04-28 | 2025-12-31 | |
| 8-K | — | 2026-04-15 | — | |
| 8-K | — | 2026-04-03 | 2026-04-02 | |
| 10-K | — | 2026-03-12 | 2025-12-31 | |
| 8-K | — | 2026-03-09 | 2026-03-06 | |
| 8-K | — | 2026-02-27 | — | |
| 8-K | — | 2026-01-27 | — | |
| 8-K | — | 2026-01-21 | 2026-01-20 | |
| 8-K | — | 2025-11-06 | — | |
| 10-Q | — | 2025-11-06 | 2025-09-30 | |
| 8-K | — | 2025-10-14 | — | |
| 8-K | — | 2025-10-08 | — | |
| 8-K | — | 2025-08-07 | — | |
| 10-Q | — | 2025-08-07 | 2025-06-30 | |
| 8-K | — | 2025-07-15 | — | |
| 8-K | — | 2025-06-26 | — | |
| 8-K | — | 2025-06-17 | — | |
| 8-K | — | 2025-06-13 | 2025-06-10 | |
| 8-K | — | 2025-06-10 | — | |
| 8-K | — | 2025-05-08 | — | |
| 10-Q | — | 2025-05-08 | 2025-03-31 | |
| DEFA14A | — | 2025-04-25 | — | |
| DEF 14A | — | 2025-04-25 | — | |
| 8-K | — | 2025-02-27 | — |
Showing 1–50 of 142 filings